Cure My Disease

Don't miss your cure!

 Log in / Sign up

Twice-Yearly HIV shots could replace daily pills

NCT ID NCT07682961

Recruiting now Disease control Sponsor: Gilead Sciences Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 23, 2026 · Updated 3 times

Summary

This phase 3 trial tests whether a combination of two antibodies (teropavimab and zinlirvimab) plus the drug lenacapavir, given as injections twice a year, can keep HIV under control in adults whose virus is already well-suppressed by daily oral medication. The study compares this approach to standard injections of cabotegravir and rilpivirine given every 8 weeks. The main goal is to see if the twice-yearly regimen is as effective at maintaining undetectable HIV levels after one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
lenacapavir, teropavimab, and zinlirvimab
What this could lead to
If successful, this could offer people with HIV a twice-yearly injection option, reducing the need for frequent shots or daily pills.
What could go wrong
This is a phase 3 trial, but the new combination may not be as effective as current treatments, and some participants may experience side effects or viral rebound.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Be Well Medical Center

    RECRUITING

    Berkley, Michigan, 48072, United States

  • CAN Community Health Fort Lauderdale

    RECRUITING

    Fort Lauderdale, Florida, 33316, United States

  • Midway Immunology and Research Center

    RECRUITING

    Ft. Pierce, Florida, 34982, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.